Clinical Trial Update: Pazopanib in Patients With Relapsed or Refractory Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating pazopanib in patients with relapsed or refractory small cell lung cancer has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Cancer
• Small Cell Lung Cancer

Drugs mentioned

• Pazopanib (Pazopanib)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Small Cell Lung Cancer, Lung Cancer | Phase 2 | Status: COMPLETED | Results posted: 2016-01-12